» Articles » PMID: 20501863

Identification of Genes Correlated with Early-stage Bladder Cancer Progression

Overview
Specialty Oncology
Date 2010 May 27
PMID 20501863
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Transitional cell carcinoma (TCC) of the bladder ranks fourth in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain poorly understood. There are also few useful diagnostic or prognostic biomarkers for this disease. We have combined a transgenic mouse model for invasive bladder cancer (UPII-SV40Tag mice) with DNA microarray technology to determine molecular mechanisms involved in early TCC development and to identify new biomarkers for detection, diagnosis, and prognosis of TCC. We have identified genes that are differentially expressed between the bladders of UPII-SV40Tag mice and their age-matched wild-type littermates at 3, 6, 20, and 30 weeks of age. These are ages that correspond to premalignant, carcinoma in situ, and early-stage and later stage invasive TCC, respectively. Our preliminary analysis of the microarray data sets has revealed approximately 1,900 unique genes differentially expressed (> or =3-fold difference at one or more time points) between wild-type and UPII-SV40Tag urothelium during the time course of tumor development. Among these, there were a high proportion of cell cycle regulatory genes and a proliferation signaling genes that are more strongly expressed in the UPII-SV40Tag bladder urothelium. We show that several of the genes upregulated in UPII-SV40Tag urothelium, including RacGAP1, PCNA, and Hmmr, are expressed at high levels in superficial bladder TCC patient samples. These findings provide insight into the earliest events in the development of bladder TCC as well as identify several promising early-stage biomarkers.

Citing Articles

The Expression Regulation and Cancer-Promoting Roles of RACGAP1.

Lin J, Zhu Y, Lin Z, Yu J, Lin X, Lai W Biomolecules. 2025; 15(1).

PMID: 39858398 PMC: 11760467. DOI: 10.3390/biom15010003.


RACGAP1 promotes lung cancer cell proliferation through the PI3K/AKT signaling pathway.

Xu Z, Wu S, Tu J, Wang M, Liang W, Cheng J Sci Rep. 2024; 14(1):8694.

PMID: 38622149 PMC: 11018837. DOI: 10.1038/s41598-024-58539-0.


and in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data.

Wu S, Nitschke K, Heinkele J, Weis C, Worst T, Eckstein M Cancers (Basel). 2019; 11(12).

PMID: 31766561 PMC: 6966660. DOI: 10.3390/cancers11121840.


Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition.

Wu P, Onodera Y, Recuenco F, Giaccia A, Le Q, Shimizu S Cancers (Basel). 2019; 11(8).

PMID: 31426369 PMC: 6721563. DOI: 10.3390/cancers11081192.


Understanding the biology of urothelial cancer metastasis.

Kobayashi T Asian J Urol. 2017; 3(4):211-222.

PMID: 29264189 PMC: 5730871. DOI: 10.1016/j.ajur.2016.09.005.


References
1.
Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer S . Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression. Clin Cancer Res. 2006; 12(3 Pt 1):969-79. DOI: 10.1158/1078-0432.CCR-05-1648. View

2.
Cheepala S, Yin W, Syed Z, Gill J, McMillian A, Kleiner H . Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer. 2009; 8:27. PMC: 2685120. DOI: 10.1186/1476-4598-8-27. View

3.
Shariat S, Karakiewicz P, Ashfaq R, Lerner S, Palapattu G, Cote R . Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2007; 112(2):315-25. DOI: 10.1002/cncr.23162. View

4.
Alvarez A, Lokeshwar V . Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007; 17(5):341-6. DOI: 10.1097/MOU.0b013e3282c8c72b. View

5.
Kong Q, Liu J, Chen X, Wang X, Sun Y, Li H . Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep. 2002; 10(1):51-5. View